OxyContin OP 10mg is an abuse-deterrent, extended-release oxycodone formulation classified as a Schedule II controlled substance. This lower-strength tablet is designed for around-the-clock management of moderate to severe chronic pain in opioid-tolerant patients. The “OP” designation indicates it contains physical and chemical barriers to deter crushing, snorting, or injecting, though it still carries significant risks of misuse and addiction.
Oxycontin OP 10mg
OxyContin OP 10mg is a prescription opioid pain medication designed to treat moderate to severe chronic pain. This formulation uses an advanced tamper-resistant technology to prevent misuse, providing extended pain relief for up to 12 hours. The active ingredient, oxycodone, helps alter the way the brain and nervous system perceive pain, offering effective long-term relief for patients with conditions like arthritis or back pain. Due to its potency, OxyContin OP 10 mg should only be used as prescribed by a healthcare provider to minimize the risks of addiction and overdose. Always follow your doctor’s instructions for safe use.
Medical Uses & Indications
FDA-Approved Uses
Moderate to severe chronic pain requiring continuous opioid therapy
Cancer pain management in opioid-tolerant patients
Pain uncontrolled by immediate-release opioids
Key Clinical Features
• Formulation: Abuse-deterrent extended-release
• Onset: 1-2 hours
• Duration: 12-hour controlled release
• Equianalgesic ratio: 10mg q12h ≈ 15mg oral morphine daily
• DEA Classification: Schedule II (High abuse potential)
Pharmacology & Mechanism
Neurochemical Action
• Full μ-opioid receptor agonist
• κ-opioid receptor partial agonist
• Sustained activation of pain modulation pathways
Abuse-Deterrent Properties
• Hard plastic coating resists crushing
• Viscous gel formation when dissolved
• Not completely abuse-proof (oral abuse still possible)
Dosing & Administration
Standard Protocol
• Initial dose for opioid-tolerant patients: 10mg q12h
• Titration: Adjust by 5-10mg increments every 3-7 days
• Maximum daily dose: 80mg without specialist consultation
Critical Safety Notes
Not for opioid-naïve patients
Must swallow whole (never cut/crush/chew)
Naloxone co-prescription required
Daily PDMP monitoring recommended
Safety Profile
Common Adverse Effects
• Constipation (prophylaxis required)
• Nausea/vomiting (30-40%)
• Dizziness/sedation
• Pruritus (20-25%)
Black Box Warnings
High potential for addiction and abuse
Life-threatening respiratory depression
Accidental exposure danger
Neonatal opioid withdrawal syndrome
Risk Mitigation Strategies
Prescribing Safeguards
-
Documented failure of non-opioid alternatives
-
Written opioid treatment agreement
-
Weekly follow-ups for first month
-
Random urine drug screens
Patient Education
• Never share medication
• Recognize overdose signs
• Proper storage in locked container
• Avoid all CNS depressants
Clinical Alternatives
For Chronic Pain
• Xtampza ER (abuse-deterrent oxycodone)
• Morphine sulfate ER
• Tapentadol ER
Non-Opioid Options
• Duloxetine (For neuropathic pain)
• Gabapentin enacarbil
• Interventional pain procedures
Special Population Considerations
| Population | Dosing Adjustment | Monitoring |
|---|---|---|
| Elderly (≥65) | Start with 5mg q12h | Increased fall risk |
| Hepatic impairment | 50% dose reduction | LFT monitoring |
| Renal (CrCl<30) | q18h dosing | Renal function |
| Pediatric | CONTRAINDICATED | – |